Deutsche Bank Maintains Buy on Maravai LifeSciences, Lowers Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Deutsche Bank analyst Justin Bowers has maintained a 'Buy' rating on Maravai LifeSciences (NASDAQ:MRVI) but lowered the price target from $23 to $17.

August 08, 2023 | 4:23 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Deutsche Bank has maintained a 'Buy' rating on Maravai LifeSciences but lowered the price target from $23 to $17.
While the 'Buy' rating is maintained, the lowering of the price target could indicate a potential decrease in the short-term value of the stock. However, the impact on the stock price is uncertain as the 'Buy' rating suggests that the stock is still expected to perform well in the long run.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100